Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Srinivas
Nuggehally R
NR
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors; D000924:Anticholesteremic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D000069059:Atorvastatin; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions; D006538:Heptanoic Acids / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters / Q000037:antagonists & inhibitors*; D011687:Purines / Q000493:pharmacokinetics / Q000494:pharmacology; D011758:Pyrroles / Q000493:pharmacokinetics / Q000494:pharmacology*; D012293:Rifampin / Q000493:pharmacokinetics / Q000494:pharmacology; D014700:Verapamil / Q000493:pharmacokinetics / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000924:Anticholesteremic Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D006538:Heptanoic Acids; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters; D011687:Purines; D011758:Pyrroles; C503999:SLCO1B1 protein, human; C111599:istradefylline; D000069059:Atorvastatin; D014700:Verapamil; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D012293:Rifampin